Digging up the human genome: Current progress in deciphering adverse drug reactions

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Su, Shih Chi ^a   Chung, Wen Hung ^a,b   Hung, Shuen Iu ^c  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALLOPURINOL; AMINOPENICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; BIOLOGICAL MARKER; CARBAMAZEPINE; CARRIER PROTEIN; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; DAPSONE; DRUG METABOLIZING ENZYME; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUCLOXACILLIN; GLUCURONOSYLTRANSFERASE 1A1; HLA ANTIGEN; LAMOTRIGINE; LUMIRACOXIB; METHAZOLAMIDE; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN 1; NEVIRAPINE; ORGANIC CATION TRANSPORTER 2; OXCARBAZEPINE; OXICAM DERIVATIVE; PHENYTOIN; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; SULFAMETHOXAZOLE; THIOPURINE METHYLTRANSFERASE;

ADVERSE DRUG REACTION; ALLELE; AUSTRALIAN; CAUCASIAN; CHINESE; DELAYED HYPERSENSITIVITY; DRESS SYNDROME; ETHNIC GROUP; EUROPEAN; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HUMAN GENOME; ITALIAN; JAPANESE; KOREAN; PATHOGENESIS; PHARMACOGENOMICS; PREDICTION; REVIEW; STEVENS JOHNSON SYNDROME; THAI; TOXIC EPIDERMAL NECROLYSIS; TOXIC HEPATITIS; DNA SEQUENCE; DRUG SURVEILLANCE PROGRAM; GENETICS; GENOMICS; METABOLISM; PHARMACOGENETICS; PHENOTYPE; TRANSPORT AT THE CELLULAR LEVEL;

ADVERSE DRUG REACTION REPORTING SYSTEMS; BIOLOGICAL MARKERS; BIOLOGICAL TRANSPORT; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GENETIC VARIATION; GENOME, HUMAN; GENOMICS; HLA ANTIGENS; HUMANS; PHARMACOGENETICS; PHENOTYPE; SEQUENCE ANALYSIS, DNA;

EID: 84897557155     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/824343     Document Type: Review

References (93)

1. Lazarou J., Pomeranz B. H., Corey P. N., Incidence of adverse drug reactions in hospitalized patients: a meta- analysis of prospective studies. Journal of the American Medical Association 1998 279 15 1200 1205 2-s2.0-0032522873 10.1001/jama.279.15.1200 (Pubitemid 28193431)
2. Rawlings M. D., Thompson J. W., Davis D. M., Mechanisms of adverse drug reactions. Textbook of Adverse Drug Reactions 1991 Oxford, UK Oxford University Press 18 45
3. Lasser K. E., Allen P. D., Woolhandler S. J., Himmelstein D. U., Wolfe S. M., Bor D. H., Timing of new black box warnings and withdrawals for prescription medications. Journal of the American Medical Association 2002 287 17 2215 2220 2-s2.0-0036570099 (Pubitemid 34441937)
4. DiMasi J. A., Hansen R. W., Grabowski H. G., The price of innovation: bew estimates of drug development costs. Journal of Health Economics 2003 22 2 151 185 2-s2.0-0037374498 10.1016/S0167-6296(02)00126-1 (Pubitemid 36279392)
5. Risch N., Merikangas K., The future of genetic studies of complex human diseases. Science 1996 273 5281 1516 1517 2-s2.0-0029741063 (Pubitemid 26301653)
6. Ioannidis J. P. A., Ntzani E. E., Trikalinos T. A., Contopoulos-Ioannidis D. G., Replication validity of genetic association studies. Nature Genetics 2001 29 3 306 309 2-s2.0-0035179971 10.1038/ng749 (Pubitemid 33096456)
7. Schmutz J., Wheeler J., Grimwood J., Dickson M., Yang J., Caolle C., Bajorek E., Black S., Chan Y. M., Denys M., Escobar J., Flowers D., Fotopulos D., Garcia C., Gomez M., Gonzales E., Haydu L., Lopez F., Ramirez L., Retterer J., Rodriguez A., Rogers S., Salazar A., Tsai M., Myers R. M., Quality assessment of the human genome sequence. Nature 2004 429 6990 365 368 2-s2.0-2642580020 10.1038/nature02390 (Pubitemid 38715122)
8. The International HapMap Consortium, A haplotype map of the human genome. Nature 2005 437 7063 1299 1320 10.1038/nature04226 (Pubitemid 41568671)
9. Hardy J., Singleton A., Genomewide association studies and human disease. The New England Journal of Medicine 2009 360 17 1759 1768 2-s2.0-65949104586 10.1056/NEJMra0808700
10. Daly A. K., Using genome-wide association studies to identify genes important in serious adverse drug reactions. Annual Review of Pharmacology and Toxicology 2012 52 21 35 2-s2.0-84855906545 10.1146/annurev-pharmtox-010611- 134743
11. Rehm H. L., Disease-targeted sequencing: a cornerstone in the clinic. Nature Reviews Genetics 2013 14 4 295 300
12. Cirulli E. T., Goldstein D. B., Uncovering the roles of rare variants in common disease through whole-genome sequencing. Nature Reviews Genetics 2010 11 6 415 425 2-s2.0-77952574849 10.1038/nrg2779
13. Sim S. C., Kacevska M., Ingelman-Sundberg M., Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects. The Pharmacogenomics Journal 2013 13 1 1 11
14. Sheweita S. A., Drug-metabolizing enzymes: mechanisms and functions. Current Drug Metabolism 2000 1 2 107 132 2-s2.0-0034281087
15. Crettol S., Petrovic N., Murray M., Pharmacogenetics of phase I and phase II drug metabolism. Current Pharmaceutical Design 2010 16 2 204 219 2-s2.0-77949478928 10.2174/138161210790112674
16. Phillips K. A., Veenstra D. L., Oren E., Lee J. K., Sadee W., Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. Journal of the American Medical Association 2001 286 18 2270 2279 2-s2.0-0035861049 (Pubitemid 33063150)
17. Božina N., Bradamante V., Lovrić M., Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk. Arhiv za Higijenu Rada i Toksikologiju 2009 60 2 217 242 2-s2.0-67749127877 10.2478/10004-1254-60-2009-1885
18. Wang B., Wang J., Huang S.-Q., Su H.-H., Zhou S.-F., Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance. Current Drug Metabolism 2009 10 7 781 834 2-s2.0-72949108032 10.2174/138920009789895480
19. Stojiljkovic M., Patrinos G. P., Pavlovic S., Clinical applicability of sequence variations in genes related to drug metabolism. Current Drug Metabolism 2011 12 5 445 454 2-s2.0-79955694748 10.2174/138920011795495277
20. Hulot J.-S., Bura A., Villard E., Azizi M., Remones V., Goyenvalle C., Aiach M., Lechat P., Gaussem P., Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006 108 7 2244 2247 2-s2.0-33749339075 10.1182/blood-2006-04- 013052 (Pubitemid 44497506)
21. Sim S. C., Nordin L., Andersson T. M.-L., Virding S., Olsson M., Pedersen N. L., Ingelman-Sundberg M., Association between CYP2C19 polymorphism and depressive symptoms. The American Journal of Medical Genetics B 2010 153 6 1160 1166 2-s2.0-77956108814 10.1002/ajmg.b.31081
22. Mrazek D. A., Biernacka J. M., O'Kane D. J., Black J. L., Cunningham J. M., Drews M. S., Snyder K. A., Stevens S. R., Rush A. J., Weinshilboum R. M., CYP2C19 variation and citalopram response. Pharmacogenetics and Genomics 2011 21 1 1 9 2-s2.0-78650676790 10.1097/FPC.0b013e328340bc5a
23. Zanger U. M., Turpeinen M., Klein K., Schwab M., Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Analytical and Bioanalytical Chemistry 2008 392 6 1093 1108 2-s2.0-54949144309 10.1007/s00216-008-2291-6
24. Gasche Y., Daali Y., Fathi M., Chiappe A., Cottini S., Dayer P., Desmeules J., Codeine intoxication associated with ultrarapid CYP2D6 metabolism. The New England Journal of Medicine 2004 351 27 2827 2831 2-s2.0-11144221180 10.1056/NEJMoa041888 (Pubitemid 40051906)
25. Kirchheiner J., Nickchen K., Bauer M., Wong M.-L., Licinio J., Roots I., Brockmöller J., Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Molecular Psychiatry 2004 9 5 442 473 2-s2.0-3142519666 10.1038/sj.mp.4001494 (Pubitemid 38903502)
26. Innocenti F., Ratain M. J., Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping. Pharmacogenomics 2006 7 8 1211 1221 2-s2.0-33845893608 10.2217/14622416.7.8.1211 (Pubitemid 46024184)
27. Toffoli G., Cecchin E., Corona G., Russo A., Buonadonna A., D'Andrea M., Pasetto L. M., Pessa S., Errante D., De Pangher V., Giusto M., Medici M., Gaion F., Sandri P., Galligioni E., Bonura S., Boccalon M., Biason P., Frustaci S., The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. Journal of Clinical Oncology 2006 24 19 3061 3068 2-s2.0-33745972934 10.1200/JCO.2005.05.5400 (Pubitemid 46638941)
28. Eichelbaum M., Ingelman-Sundberg M., Evans W. E., Pharmacogenomics and individualized drug therapy. Annual Review of Medicine 2006 57 119 137 2-s2.0-32944454759 10.1146/annurev.med.56.082103.104724 (Pubitemid 43261982)
29. Heckmann J. M., Lambson E. M. T., Little F., Owen E. P., Thiopurine methyltransferase (TPMT) heterozygosity and enzyme activity as predictive tests for the development of azathioprine-related adverse events. Journal of the Neurological Sciences 2005 231 1-2 71 80 2-s2.0-15944394455 10.1016/j.jns.2005. 01.003 (Pubitemid 40432029)
30. Evans W. E., Hon Y. Y., Bomgaars L., Coutre S., Holdsworth M., Janco R., Kalwinsky D., Keller F., Khatib Z., Margolin J., Murray J., Quinn J., Ravindranath Y., Ritchey K., Roberts W., Rogers Z. R., Schiff D., Steuber C., Tucci F., Kornegay N., Krynetski E. Y., Relling M. V., Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. Journal of Clinical Oncology 2001 19 8 2293 2301 2-s2.0-0035871560 (Pubitemid 32366982)
31. Sim E., Pharmacogenomics of arylamine N-acetyltransferases-from drug metabolism to drug discovery. Pharmacogenomics 2002 3 6 729 731 2-s2.0-0036850234 10.1517/14622416.3.6.729 (Pubitemid 35331408)
32. Das K. M., Dubin R., Clinical pharmacokinetics of sulphasalazine. Clinical Pharmacokinetics 1976 1 6 406 425 2-s2.0-0017151106
33. Lemke L. E., McQueen C. A., Acetylation and its role in the mutagenicity of the antihypertensive agent hydralazine. Drug Metabolism and Disposition 1995 23 5 559 565 2-s2.0-0029068479
34. Strandberg I., Boman G., Hassler L., Sjoqvist F., Acetylator phenotype in patients with hydralazine induced lupoid syndrome. Acta Medica Scandinavica 1976 200 5 367 371 2-s2.0-0017146043
35. Klaassen C. D., Aleksunes L. M., Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacological Reviews 2010 62 1 1 96 2-s2.0-77949398878 10.1124/pr.109.002014
36. Degorter M. K., Xia C. Q., Yang J. J., Kim R. B., Drug transporters in drug efficacy and toxicity. Annual Review of Pharmacology and Toxicology 2012 52 249 273 2-s2.0-84855904426 10.1146/annurev-pharmtox-010611-134529
37. Niemi M., Pasanen M. K., Neuvonen P. J., Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacological Reviews 2011 63 1 157 181 2-s2.0-79953901458 10.1124/pr.110.002857
38. Link E., Parish S., Armitage J., Bowman L., Heath S., Matsuda F., Gut I., Lathrop M., Collins R., Meade T., Sleight P., Collins R., Armitage J., Parish S., Barton J., Bray C., Wincott E., Bowman L., Clarke R., Graham I., Simpson D., Warlow C., Wilcken D., Tobert J., Musliner T., Wilhelmsen L., Doll R., Fox K. M., Hill C., Sandercock P., Peto R., SLCO1B1 variants and statin-induced myopathy-a genomewide study. The New England Journal of Medicine 2008 359 8 789 799 2-s2.0-49949104757 10.1056/NEJMoa0801936
39. Brunham L. R., Lansberg P. J., Zhang L., Miao F., Carter C., Hovingh G. K., Visscher H., Jukema J. W., Stalenhoef A. F., Ross C. J. D., Carleton B. C., Kastelein J. J. P., Hayden M. R., Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics Journal 2012 12 3 233 237 2-s2.0-78651393542 10.1038/tpj.2010.92
40. Wilke R. A., Ramsey L. B., Johnson S. G., The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clinical Pharmacology & Therapeutics 2012 92 1 112 117
41. Filipski K. K., Mathijssen R. H., Mikkelsen T. S., Schinkel A. H., Sparreboom A., Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clinical Pharmacology & Therapeutics 2009 86 4 396 402 2-s2.0-70349440952 10.1038/clpt.2009.139
42. Han Y.-F., Fan X.-H., Wang X.-J., Sun K., Xue H., Li W.-J., Wang Y.-B., Chen J.-Z., Zhen Y.-S., Zhang W.-L., Zhou X., Hui R., Association of intergenic polymorphism of organic anion transporter 1 and 3 genes with hypertension and blood pressure response to hydrochlorothiazide. The American Journal of Hypertension 2011 24 3 340 346 2-s2.0-79951675822 10.1038/ajh.2010.191
43. Gottesman M. M., Pastan I., Biochemistry of multidrug resistance mediated by the multidrug transporter. Annual Review of Biochemistry 1993 62 385 427 2-s2.0-0027218689 (Pubitemid 23237876)
44. Hauser I. A., Schaeffeler E., Gauer S., Scheuermann E. H., Wegner B., Gossmann J., Ackermann H., Seidl C., Hocher B., Zanger U. M., Geiger H., Eichelbaum M., Schwab M., ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. Journal of the American Society of Nephrology 2005 16 5 1501 1511 2-s2.0-21444449731 10.1681/ASN.2004100882 (Pubitemid 41716536)
45. Garcia M., Macias R. M., Cubero J. J., Benitez J., Caravaca F., Gervasini G., ABCB1 polymorphisms are associated with cyclosporine-induced nephrotoxicity and gingival hyperplasia in renal transplant recipients. European Journal of Clinical Pharmacology 2013 69 3 385 393
46. Johne A., Köpke K., Gerloff T., Mai I., Rietbrock S., Meisel C., Hoffmeyer S., Kerb R., Fromm M. F., Brinkmann U., Eichelbaum M., Brockmöller J., Cascorbi I., Roots I., Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clinical Pharmacology & Therapeutics 2002 72 5 584 594 2-s2.0-0036881149 10.1067/mcp.2002.129196 (Pubitemid 36237730)
47. Chowbay B., Cumaraswamy S., Cheung Y. B., Zhou Q., Lee E. J. D., Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 2003 13 2 89 95 2-s2.0-0037330517 10.1097/00008571-200302000- 00005 (Pubitemid 36259588)
48. Yi S.-Y., Hong K.-S., Lim H.-S., Chung J.-Y., Oh D.-S., Kim J.-R., Jung H.-R., Cho J.-Y., Yu K.-S., Jang I.-J., Shin S.-G., A variant 2677A allele of the MDR1 gene affects fexofenadine disposition. Clinical Pharmacology & Therapeutics 2004 76 5 418 427 2-s2.0-7944236606 10.1016/j.clpt.2004.08.002 (Pubitemid 39469866)
49. Low S.-K., Kiyotani K., Mushiroda T., Daigo Y., Nakamura Y., Zembutsu H., Association study of genetic polymorphism in ABCC4 with cyclophosphamide- induced adverse drug reactions in breast cancer patients. Journal of Human Genetics 2009 54 10 564 571 2-s2.0-70350449053 10.1038/jhg.2009.79
50. Ansari M., Sauty G., Labuda M., Gagné V., Laverdière C., Moghrabi A., Sinnett D., Krajinovic M., Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia. Blood 2009 114 7 1383 1386 2-s2.0-70349331568 10.1182/blood-2008-11-191098
51. Martin A. M., Nolan D., Gaudieri S., Almeida C. A., Nolan R., James I., Carvalho F., Phillips E., Christiansen F. T., Purcell A. W., McCluskey J., Mallal S., Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proceedings of the National Academy of Sciences of the United States of America 2004 101 12 4180 4185 2-s2.0-12144287198 10.1073/pnas.0307067101 (Pubitemid 38405903)
52. Mallal S., Nolan D., Witt C., Masel G., Martin A. M., Moore C., Sayer D., Castley A., Mamotte C., Maxwell D., James I., Christiansen F. T., Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. The Lancet 2002 359 9308 727 732 2-s2.0-0037006623 10.1016/S0140-6736(02)07873-X (Pubitemid 34215071)
53. Tassaneeyakul W., Jantararoungtong T., Chen P., Lin P.-Y., Tiamkao S., Khunarkornsiri U., Chucherd P., Konyoung P., Vannaprasaht S., Choonhakarn C., Pisuttimarn P., Sangviroon A., Tassaneeyakul W., Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenetics and Genomics 2009 19 9 704 709 2-s2.0-70249122727 10.1097/FPC.0b013e328330a3b8
54. Kaniwa N., Saito Y., Aihara M., Matsunaga K., Tohkin M., Kurose K., Sawada J.-I., Furuya H., Takahashi Y., Muramatsu M., Kinoshita S., Abe M., Ikeda H., Kashiwagi M., Song Y., Ueta M., Sotozono C., Ikezawa Z., Hasegawa R., HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 2008 9 11 1617 1622 2-s2.0-61549115662 10.2217/14622416.9.11.1617
55. Lonjou C., Borot N., Sekula P., Ledger N., Thomas L., Halevy S., Naldi L., Bouwes-Bavinck J.-N., Sidoroff A., De Toma C., Schumacher M., Roujeau J.-C., Hovnanian A., Mockenhaupt M., A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenetics and Genomics 2008 18 2 99 107 2-s2.0-38149108354 10.1097/FPC.0b013e3282f3ef9c
56. Hung S.-L., Chung W.-H., Liou L.-B., Chu C.-C., Lin M., Huang H.-P., Lin Y.-L., Lan J.-L., Yang L.-C., Hong H.-S., Chen M.-J., Lai P.-C., Wu M.-S., Chu C.-Y., Wang K.-H., Chen C.-H., Fann C. S. J., Wu J.-Y., Chen Y.-T., HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proceedings of the National Academy of Sciences of the United States of America 2005 102 11 4134 4139 2-s2.0-15244349566 10.1073/pnas.0409500102 (Pubitemid 40388568)
57. Romano A., de Santis A., Romito A., Di Fonso M., Venuti A., Gasbarrini G. B., Manna R., Delayed hypersensitivity to aminopenicillins is related to major histocompatibility complex genes. Annals of Allergy, Asthma & Immunology 1998 80 5 433 437 2-s2.0-0031861918 (Pubitemid 28246777)
58. Lucena M. I., Molokhia M., Shen Y., Urban T. J., Aithal G. P., Andrade R. J., Day C. P., Ruizcabello F., Donaldson P. T., Stephens C., Pirmohamed M., Romerogomez M., Navarro J. M., Fontana R. J., Miller M., Groome M., Bondonguitton E., Conforti A., Stricker B. H. C., Carvajal A., Ibanez L., Yue Q., Eichelbaum M., Floratos A., Pe'Er I., Daly M. J., Goldstein D. B., Dillon J. F., Nelson M. R., Watkins P. B., Daly A. K., Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 2011 141 1 338 347 2-s2.0-79957523368 10.1053/j.gastro.2011.04.001
59. Locharernkul C., Loplumlert J., Limotai C., Korkij W., Desudchit T., Tongkobpetch S., Kangwanshiratada O., Hirankarn N., Suphapeetiporn K., Shotelersuk V., Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia 2008 49 12 2087 2091 2-s2.0-57449118501 10.1111/j.1528-1167.2008.01719.x
60. Chung W.-H., Hung S.-I., Hong H.-S., Hsih M.-S., Yang L.-C., Ho H.-C., Wu J.-Y., Chen Y.-T., Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004 428 6982 486 2-s2.0-1842484777 (Pubitemid 38480527)
61. Man C. B., Kwan P., Baum L., Yu E., Lau K. M., Cheng A. S., Ng M. H., Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 2007 48 5 1015 1018 (Pubitemid 46763406)
62. Mehta T. Y., Prajapati L. M., Mittal B., Joshi C. G., Sheth J. J., Patel D. B., Dave D. M., Goyal R. K., Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. Indian Journal of Dermatology, Venereology and Leprology 2009 75 6 579 582 2-s2.0-70450205028 10.4103/0378-6323.57718
63. Kaniwa N., Saito Y., Aihara M., Matsunaga K., Tohkin M., Kurose K., Furuya H., Takahashi Y., Muramatsu M., Kinoshita S., Abe M., Ikeda H., Kashiwagi M., Song Y., Ueta M., Sotozono C., Ikezawa Z., Hasegawa R., HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia 2010 51 12 2461 2465 2-s2.0-78650007285 10.1111/j.1528-1167.2010.02766.x
64. Ikeda H., Takahashi Y., Yamazaki E., Fujiwara T., Kaniwa N., Saito Y., Aihara M., Kashiwagi M., Muramatsu M., HLA class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions. Epilepsia 2010 51 2 297 300 2-s2.0-75649107833 10.1111/j.1528-1167.2009.02269.x
65. McCormack M., Alfirevic A., Bourgeois S., Farrell J. J., Kasperavičiute D., Carrington M., Sills G. J., Marson T., Jia X., De Bakker P. I. W., Chinthapalli K., Molokhia M., Johnson M. R., O'Connor G. D., Chaila E., Alhusaini S., Shianna K. V., Radtke R. A., Heinzen E. L., Walley N., Pandolfo M., Pichler W., Park B. K., Depondt C., Sisodiya S. M., Goldstein D. B., Deloukas P., Delanty N., Cavalleri G. L., Pirmohamed M., HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. The New England Journal of Medicine 2011 364 12 1134 1143 2-s2.0-79953197983 10.1056/NEJMoa1013297
66. Hung S.-I., Chung W.-H., Jee S.-H., Chen W.-C., Chang Y.-T., Lee W.-R., Hu S.-L., Wu M.-T., Chen G.-S., Wong T.-W., Hsiao P.-F., Chen W.-H., Shih H.-Y., Fang W.-H., Wei C.-Y., Lou Y.-H., Huang Y.-L., Lin J.-J., Chen Y.-T., Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenetics and Genomics 2006 16 4 297 306 2-s2.0-33645082244 10.1097/01.fpc.0000199500.46842.4a
67. Niihara H., Kakamu T., Fujita Y., Kaneko S., Morita E., HLA-A31 strongly associates with carbamazepine-induced adverse drug reactions but not with carbamazepine-induced lymphocyte proliferation in a Japanese population. The Journal of Dermatology 2012 39 7 594 601 2-s2.0-84855165062 10.1111/j.1346-8138. 2011.01457.x
68. Zhang F. R., Liu H., Irwanto A., HLA-B*13:01 and the dapsone hypersensitivity syndrome. The New England Journal of Medicine 2013 369 17 1620 1628
69. Daly A. K., Donaldson P. T., Bhatnagar P., Shen Y., Pe'Er I., Floratos A., Daly M. J., Goldstein D. B., John S., Nelson M. R., Graham J., Park B. K., Dillon J. F., Bernal W., Cordell H. J., Pirmohamed M., Aithal G. P., Day C. P., HLA-B5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nature Genetics 2009 41 7 816 819 2-s2.0-67649859295 10.1038/ng.379
70. Hung S.-I., Chung W.-H., Liu Z.-S., Chen C.-H., Hsih M.-S., Hui R. C.-Y., Chu C.-Y., Chen Y.-T., Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics 2010 11 3 349 356 2-s2.0-77949600882 10.2217/pgs.09.162
71. Kazeem G. R., Cox C., Aponte J., Messenheimer J., Brazell C., Nelsen A. C., Nelson M. R., Foot E., High-resolution HLA genotyping and severe cutaneous adverse reactions in lamotrigine-treated patients. Pharmacogenetics and Genomics 2009 19 9 661 665 2-s2.0-70249102418 10.1097/FPC.0b013e32832c347d
72. Singer J. B., Lewitzky S., Leroy E., Yang F., Zhao X., Klickstein L., Wright T. M., Meyer J., Paulding C. A., A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nature Genetics 2010 42 8 711 714 2-s2.0-77955082302 10.1038/ng.632
73. Kim S.-H., Kim M., Lee K. W., Kim S.-H., Kang H.-R., Park H.-W., Jee Y.-K., HLA-B*5901 is strongly associated with methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. Pharmacogenomics 2010 11 6 879 884 2-s2.0-77952937737 10.2217/pgs.10.54
74. Chantarangsu S., Mushiroda T., Mahasirimongkol S., Kiertiburanakul S., Sungkanuparph S., Manosuthi W., Tantisiriwat W., Charoenyingwattana A., Sura T., Chantratita W., Nakamura Y., HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients. Pharmacogenetics and Genomics 2009 19 2 139 146 2-s2.0-59549096348 10.1097/FPC.0b013e32831d0faf
75. Martin A. M., Nolan D., James I., Cameron P., Keller J., Moore C., Phillips E., Christiansen F. T., Mallal S., Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS 2005 19 1 97 99 2-s2.0-12144260460 (Pubitemid 40111026)
76. Pavlos R., Mallal S., Phillips E., HLA and pharmacogenetics of drug hypersensitivity. Pharmacogenomics 2012 13 11 1285 1306
77. Pohl L. R., Satoh H., Christ D. D., Kenna J. G., The immunologic and metabolic basis of drug hypersensitivities. Annual Review of Pharmacology and Toxicology 1988 28 367 387 2-s2.0-0023893095
78. Padovan E., Bauer T., Tongio M. M., Kalbacher H., Weltzien H. U., Penicilloyl peptides are recognized as T cell antigenic determinants in penicillin allergy. European Journal of Immunology 1997 27 6 1303 1307 2-s2.0-0030918532 10.1002/eji.1830270602 (Pubitemid 27254817)
79. Pichler W. J., Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept. Current Opinion in Allergy and Clinical Immunology 2002 2 4 301 305 2-s2.0-0036676978 (Pubitemid 36869638)
80. Illing P. T., Vivian J. P., Dudek N. L., Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature 2012 486 7404 554 558
81. Ostrov D. A., Grant B. J., Pompeu Y. A., Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proceedings of the National Academy of Sciences of the United States of America 2012 109 25 9959 9964
82. Norcross M. A., Luo S., Lu L., Abacavir induces loading of novel self-peptides into HLA-B*57: 01: an autoimmune model for HLA-associated drug hypersensitivity. AIDS 2012 26 11 F21 F29
83. Ozeki T., Mushiroda T., Yowang A., Takahashi A., Kubo M., Shirakata Y., Ikezawa Z., Iijima M., Shiohara T., Hashimoto K., Kamatani N., Nakamura Y., Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Human Molecular Genetics 2011 20 5 1034 1041 2-s2.0-79551600984 10.1093/hmg/ddq537
84. Vitezica Z. G., Milpied B., Lonjou C., Borot N., Ledger T. N., Lefebvre A., Hovnanian A., HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz. AIDS 2008 22 4 540 541 2-s2.0-39849105346 10.1097/QAD.0b013e3282f37812 (Pubitemid 351317299)
85. Choi J. H., Lee K. W., Oh H. B., Lee K. J., Suh Y. J., Park C. S., Park H.-S., HLa association in aspirin-intolerant asthma: DPB1*0301 as a strong marker in a Korean population. Journal of Allergy and Clinical Immunology 2004 113 3 562 564 2-s2.0-1542407022 10.1016/j.jaci.2003.12.012 (Pubitemid 38338966)
86. Spraggs C. F., Budde L. R., Briley L. P., Bing N., Cox C. J., King K. S., Whittaker J. C., Mooser V. E., Preston A. J., Stein S. H., Cardon L. R., HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. Journal of Clinical Oncology 2011 29 6 667 673 2-s2.0-79952173247 10.1200/JCO.2010.31.3197
87. Sakamoto K., Oka M., Yoshino S., Hazama S., Abe T., Okayama N., Hinoda Y., Relation between cytokine promoter gene polymorphism and toxicity of 5-fluorouracil plus cisplatin chemotherapy. Oncology Reports 2006 16 2 381 387 2-s2.0-33748530651
88. Park H.-J., Ye Y.-M., Hur G.-Y., Kim S.-H., Park H.-S., Association between a TGF β 1 promoter polymorphism and the phenotype of aspirin-intolerant chronic urticaria in a Korean population. Journal of Clinical Pharmacy and Therapeutics 2008 33 6 691 697 2-s2.0-55949092020 10.1111/j.1365-2710.2008.00957.x
89. Kim S.-H., Yang E.-M., Lee H.-N., Cho B.-Y., Ye Y.-M., Park H.-S., Combined effect of IL-10 and TGF- β 1 promoter polymorphisms as a risk factor for aspirin-intolerant asthma and rhinosinusitis. Allergy 2009 64 8 1221 1225 2-s2.0-67650287069 10.1111/j.1398-9995.2009.01989.x
90. Graziano F., Ruzzo A., Loupakis F., Canestrari E., Santini D., Catalano V., Bisonni R., Torresi U., Floriani I., Schiavon G., Andreoni F., Maltese P., Rulli E., Humar B., Falcone A., Giustini L., Tonini G., Fontana A., Masi G., Magnani M., Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. Journal of Clinical Oncology 2008 26 9 1427 1434 2-s2.0-41149140325 10.1200/JCO.2007.12.4602
91. Giovannetti E., Zucali P. A., Peters G. J., Cortesi F., D'Incecco A., Smit E. F., Falcone A., Burgers J. A., Santoro A., Danesi R., Giaccone G., Tibaldi C., Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib. Molecular Cancer Therapeutics 2010 9 3 581 593 2-s2.0-77949686314 10.1158/1535-7163.MCT-09-0665
92. Blum K. A., Jung S.-H., Johnson J. L., Lin T. S., Hsi E. D., Lucas D. M., Byrd J. C., Cheson C. B., Bartlett N. L., Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an Fc γ RIIIa-158 V/F polymorphism. Annals of Oncology 2010 21 11 2246 2254 2-s2.0-77958490178 10.1093/annonc/mdq211
93. Yokoi T., Nakajima M., microRNAs as mediators of drug toxicity. Annual Review of Pharmacology and Toxicology 2013 53 377 400